Sandoz has entered into a binding agreement to acquire Aspen Pharmacare’s Japanese business for up to €400m ($441m). The two companies expect to complete the cash transaction during the first half of 2020, subject to satisfying certain conditions that include antitrust clearance from Japan’s Fair Trade Commission and the consent of lenders in terms of Aspen’s syndicated debt facilities.
Sandoz To Acquire Aspen’s Japanese Operations
Up to €400m Deal Strengthens Hospitals Portfolio
Sandoz is to pay up to €400m for Aspen’s anesthetics and other specialty off-patent brands in Japan, strengthening the Novartis division’s local position in the hospitals market.
